FOXO3 and osteoporosis: The bisphosphonate, zoledronic acid, originally used for osteoporosis management, is now in clinical trials as a chemotherapeutic drug; it activates FOXO3a and inhibits expression of the proangiogenic factor CCN1 (Table 2) [25].